Skip to content

SCREENER CHART SD50 CALENDAR NEWS

...

Agenus Inc. (AGEN) Stock · SELL · CRISIS | LOPJLB

Agenus Inc. (AGEN)

Healthcare

$6.95-6.46%Close

SELLCRISIS · day 6

AGEN▼ SELL

$6.95-6.46%

Overview FinancialsFin EarningsEarn Analyst & RatingsAnalyst News Holders & ETFsHold Options

Key stats

Market cap: $289M

1W: -7.21%
1M: -2.52%

vs SPY 1W: -7.63%
vs SPY 1M: -4.59%

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

Sector: Healthcare

FUNDAMENTALS

NO COVERAGE

Company news

businesswire.com · 5d ago

Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference

businesswire.com · 6d ago

Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

defenseworld.net · 8d ago

ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey

defenseworld.net · 9d ago

Agenus (NASDAQ:AGEN) Stock Keeps “Buy” Rating at Chardan Capital

gurufocus.com · 11d ago

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

businesswire.com · 11d ago

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

gurufocus.com · 12d ago

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

businesswire.com · 12d ago

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

seekingalpha.com · 33d ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

businesswire.com · 34d ago

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

defenseworld.net · 42d ago

Agenus (NASDAQ:AGEN) Stock Crosses Above 200-Day Moving Average – Here’s Why

gurufocus.com · 44d ago

Agenus to Participate in Upcoming September Investor Conferences

businesswire.com · 44d ago

Agenus to Participate in Upcoming September Investor Conferences

gurufocus.com · 47d ago

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

businesswire.com · 47d ago

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

gurufocus.com · 49d ago

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

businesswire.com · 49d ago

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

zacks.com · 67d ago

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

businesswire.com · 69d ago

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

businesswire.com · 77d ago

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Market news & ticker search · RSS for AGEN

FAQ

What is LOPJLB’s current signal on AGEN?: LOPJLB’s latest quantitative signal on Agenus Inc. (AGEN) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is AGEN in?: Agenus Inc. (AGEN) is currently classified in the CRISIS HMM market regime on LOPJLB.

LOPJLB

Independent quant research on U.S. equities & ETFs. Not personalized advice.

Product

Screener Chart Compare SD50 Thesis News Calendar

Desk

Market Heatmap Market Hours FOMC Desk Treasury Rates Congress Trades Prediction Markets

Research

How It Works Methodology Track Record Docs Editorial Blog Changelog

Ledgers

Bull Spreads Cash-Secured Puts Covered Calls Long Puts Long Calls

Screeners

CEF Screener REIT Screener BDC Screener Preferred Screener Dividend Screener ETF Screener Crypto Screener S&P 500 Screener Best dividend stocks Undervalued stocks Best S&P 500 stocks

Company

Pricing About Contact

Agents

GitHub·Research Chat·MCPENT·Developers

© 2026 LOPJLB Research. All rights reserved.

@lopjlb contact@lopjlb.com

RANGE

LOPJLB.COM

OHLC🔒EMALEVELS🔒STOP🔒FLIP🔒52WSIGNALS🔒BUY🔒SELL🔒EXH🔒EXH ZONE🔒BEST